Please use this identifier to cite or link to this item:
Type
ArticleCopyright
Open access
Collections
- INI - Artigos de Periódicos [3646]
Metadata
Show full item record
INTRALESIONAL TREATMENT WITH MEGLUMINE ANTIMONIATE IN THREE PATIENTS WITH NEW WORLD CUTANEOUS LEISHMANIASIS AND LARGE PERIARTICULAR LESIONS WITH COMORBIDITIES
Author
Affilliation
Abstract
Although New World cutaneous leishmaniasis is not itself a life-threatening disease, its treatment with systemic antimonials can cause toxicity that can be dangerous to some patients. Intralesional meglumine antimoniate provides a viable, less toxic alternative. Herein, we describe an alternative treatment with subcutaneous intralesional injections of meglumine antimoniate into large periarticular lesions of three patients with cutaneous leishmaniasis and comorbidities. This treatment was safe, successful, and well tolerated. This case series suggests that intralesional meglumine antimoniate is an effective therapy for cutaneous leishmaniasis, even with periarticular lesions. This hypothesis should be tested in controlled clinical trials.
Share